FDA approved

ARCALYST (rilonacept)

The first and only FDA-approved therapy that treats recurrent pericarditis and reduces the risk of future flares

Recurrent pericarditis can be a painful and debilitating disease. If you are experiencing repeat flares, it may be time to talk with your healthcare provider about ARCALYST. It’s the first and only FDA-approved treatment for people living with recurrent pericarditis who are 12 years and older. ARCALYST targets IL-1 and is indicated for the treatment of recurrent pericarditis and reduction in risk of future flares.

ARCALYST VILE

ARCALYST doesn't just treat recurrent pericarditis—it reduces the risk of future flares.

ARCALYST targets IL-1 an underlying cause of the ongoing inflammation in recurrent pericarditis. Not only does ARCALYST address painful symptoms, it also reduces the risk of future flares.

Why ARCALYST?

Learn about recurrent pericarditis, what causes repeat episodes, and the risk of future flares.

Understand the disease

Taking Control

Discover how ARCALYST is designed to treat recurrent pericarditis. See the powerful results from the clinical study.

See how it works

Using ARCALYST

Understand how a once-weekly injection of ARCALYST can provide effective treatment for recurrent pericarditis.

Learn more about treatment

Support for your treatment journey

Kiniksa OneConnect is a support program that provides you with personalized one-on-one support at each step of your treatment journey.

Learn how we can help

Contact Us

Important Safety Information

ARCALYST can affect your immune system and can lower the ability of your immune system to fight infections. Serious infections, including life-threatening infections and death have happened in patients taking ARCALYST. You should not begin ARCALYST if you have an infection, or have infections that keep coming back. After starting ARCALYST, if you get an infection or show any sign of an infection, including a fever, cough, flu-like symptoms, or have any open sores on your body, call your doctor right away. Treatment with ARCALYST should be stopped if you get a serious infection.
While taking ARCALYST, do not take other medicines that block interleukin-1, such as Kineret® (anakinra), or medicines that block tumor necrosis factor, such as Enbrel® (etanercept), Humira® (adalimumab), or Remicade® (infliximab), as this may increase your risk of getting a serious infection.
Before starting ARCALYST, tell your doctor if you think you have an infection, are being treated for an infection, have signs of an infection, have any open sores, have a history of infections that keep coming back, have asthma, have diabetes or an immune system problem, have tuberculosis or have been in contact with someone who has had tuberculosis, have or have had HIV, hepatitis B or hepatitis C, or take other medicines that affect your immune system.
Before you begin treatment with ARCALYST, talk with your healthcare provider about your vaccine history. Ask your healthcare provider whether you should receive any vaccines, including the pneumonia vaccine and flu vaccine, before you begin treatment with ARCALYST.
ARCALYST can cause serious side effects:
- Medicines that affect the immune system may increase the risk of getting cancer.
- Stop taking ARCALYST and call your doctor or get emergency care right away if you have any symptoms of an allergic reaction (eg, rash, swollen face, trouble breathing).
- Your doctor will do blood tests to check for changes in your blood cholesterol and triglycerides.
Common side effects of ARCALYST include injection-site reactions, upper respiratory tract infections, joint and muscle aches, rash, ear infection, sore throat, and runny nose.
Tell your doctor if you are scheduled to receive any vaccines, if you are pregnant or plan to become pregnant, and if you are breastfeeding or plan to breastfeed.
Tell your doctor if you take other medicines that affect the immune system such as interleukin-1 blockers, tumor necrosis factor blockers, or corticosteroids.

For more information about ARCALYST, talk to your doctor and see the Product Information.

INDICATION

ARCALYST® (rilonacept) is an interleukin-1 blocker indicated for:

Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older.
Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older.
Maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more.

Go Back Continue